文献速递造血干细胞移植与细胞治疗白血病淋巴瘤

II类HLA错配改善单倍体移植联合PTCy的预后

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.
PubMed 文献 · Blood Adv · 2020-01-01

该研究回顾性分析208例接受单倍体移植联合移植后环磷酰胺(PTCy)的血液恶性肿瘤患者,中位随访65.4个月。单因素分析显示,HLA-DR、HLA-DQ或非允许性HLA-DP单个II类错配与无病生存和总生存改善相关,主要归因于复发风险降低;该生存获益呈累积效应,3个II类错配者OS最佳。HLA-A、B、C位点错配则不影响急性GVHD、非复发死亡、复发或生存,但HLA-A错配与慢性GVHD发生率增加相关。

要点

  • II类HLA错配(DR、DQ或非允许性DP)与单倍体移植后生存改善相关
  • HLA-DR错配和非允许性HLA-DP错配独立与OS改善相关
  • II类错配降低复发风险且不增加NRM或GVHD

核心结论

  • 在单倍体移植联合PTCy中,II类HLA错配(HLA-DR、HLA-DQ或非允许性HLA-DP)与无病生存和总生存改善相关,主要因复发风险降低。
  • II类错配的生存获益呈累积效应,3个II类错配(HLA-DR、HLA-DQ和非允许性HLA-DP)患者OS最佳。

研究设计与样本

  • 单中心回顾性分析208例连续接受单倍体移植联合PTCy的血液恶性肿瘤患者。
  • 中位年龄52岁(范围19-75岁),外周血干细胞移植占66%,减低强度预处理占59%。
  • 中位随访65.4个月(范围34.3-157.2个月)。

主要发现

  • 单因素分析中,HLA-DR、HLA-DQ或非允许性HLA-DP单个II类错配对无病生存和OS有保护作用,主要因复发风险降低。
  • HLA-A、HLA-B或HLA-C位点单个或多个错配对急性GVHD、非复发死亡、复发或生存无影响,但HLA-A错配与慢性GVHD发生率增加相关。
  • II类错配与较低复发相关,且未伴随非复发死亡或急慢性GVHD的相应增加。

关键数值与推荐

  • 3个II类错配(HLA-DR、HLA-DQ和非允许性HLA-DP)患者OS最佳。

临床怎么用

  • 在单倍体移植联合PTCy时,II类HLA错配(尤其是HLA-DR和非允许性HLA-DP)可能与生存改善相关,可供供者选择时参考。
  • HLA-A、B、C位点错配不影响主要移植结局,但HLA-A错配与慢性GVHD增加相关,需关注。
  • 上述发现需在更大规模登记研究中验证。

局限性

  • 单中心回顾性研究,样本量208例。
  • 作者指出这些发现需要在更大规模登记研究中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HLA disparity is the major predictor of outcome following unrelated donor (UD) transplantation, where a single mismatch (mm) at the HLA-A, HLA-B, HLA-C, or HLA-DRB1 locus leads to increased mortality, and mismatching at multiple loci compounds this effect. In contrast, HLA disparity has not been shown to increase mortality in the context of haploidentical transplant using posttransplant cyclophosphamide (PTCy). To better define the consequences of loci-specific HLA mm, we analyzed 208 consecutive patients undergoing haploidentical transplantation for hematologic malignancy using PTCy at our institution (median age, 52 years [range, 19-75 years]; peripheral blood stem cell, 66%; reduced-intensity conditioning, 59%). Median follow-up was 65.4 months (range, 34.3-157.2 months). In univariate analysis, a single class II HLA mm at HLA-DR, HLA-DQ or a nonpermissive (np) HLA-DP mm had a protective effect on disease-free and overall survival (OS), primarily a result of reduced relapse risk. Furthermore, this survival effect was cumulative, so that patients with 3 class II mm (HLA-DR, HLA-DQ, and np HLA-DP) had the best OS. In multivariate analysis, HLA-DR mm and np HLA-DP mm were both independently associated with improved OS (hazard ratio [HR], 0.43; P =.001; and HR, 0.47; P =.011, respectively). In contrast, single or multiple mm at HLA-A, HLA-B, or HLA-C loci had no effect on acute graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, or survival, although the presence of an HLA-A mm was associated with increased chronic GVHD incidence. The association of class II mm with lower relapse occurred without a corresponding increase in NRM or acute or chronic GVHD. These findings will require validation in larger registry studies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Solomon SR, Aubrey MT, Zhang X, et al. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv. 2020. PMID: 33108457. doi:10.1182/bloodadvances.2020003110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。